Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01183676 · ClinicalTrials.gov registry record · Phase 1

Fed Bioequivalence Study of Divalproex Sodium Delayed-Release Tablets, 500 mg

A Phase 1 study, sponsored by Mylan Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
20
Enrollment target

NCT01183676: Completed Phase 1 study, sponsored by Mylan Pharmaceuticals.

NCT01183676 is a Phase 1 study that has completed, run by Mylan Pharmaceuticals. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01183676, a Phase 1 study, has completed, sponsored by Mylan Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
20 participants
Enrollment target

Study Summary

The objective of this study was to investigate the bioequivalence of Mylan's divalproex sodium-delayed-release tablets 500 mg tablets to Abbott's Depakote® 500 mg tablets following a single, oral 500 mg (1 x 500 mg) dose administration under fed conditions.

Primary Outcome

Maximum plasma concentration (micrograms/mL)

Interventions

  • DRUG DEPAKOTE® Tablets, 500 MG
  • DRUG DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2007-07
Est. Completion 2007-07
Phase Phase 1
Mylan Pharmaceuticals

146 total trials

What the finished NCT01183676 record still lists

NCT01183676 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).

The record links to 0 conditions, and to 2 interventions - of which DEPAKOTE® Tablets, 500 MG is the first listed.

NCT01183676 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01183676 about?

NCT01183676 is a clinical study titled "Fed Bioequivalence Study of Divalproex Sodium Delayed-Release Tablets, 500 mg". The objective of this study was to investigate the bioequivalence of Mylan's divalproex sodium-delayed-release tablets 500 mg tablets to Abbott's Depakote® 500 mg tablets following a single, oral 500 mg (1 x 500 mg) dose administration under fed conditions.

What is the current status of trial NCT01183676?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2007-07. Estimated completion is 2007-07.

What interventions are being tested in trial NCT01183676?

The interventions under investigation include: DEPAKOTE® Tablets, 500 MG (DRUG), DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG (DRUG).

Who is sponsoring clinical trial NCT01183676?

This trial is sponsored by Mylan Pharmaceuticals, which has 146 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01183676's enrollment target sits among peer trials

20 1629th of 2000 higher than 285 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01183676, the US trial registry maintained by the National Library of Medicine. NCT01183676 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.